The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma
Open accessAbstract
Purpose: To evaluate the feasibility of and response rate to an intensified induction chemotherapy regimen for young children with newly diagnosed high-risk or disseminated medulloblastomas. Patients and Methods: From January 1997 to March 2003, 21 patients with high-risk or disseminated medulloblastoma were enrolled. After maximal surgical resection, patients were treated with five cycles of vincristine (0.05 mg/kg/wk × three doses per cycle for three cycles), cisplatin (3.5 mg/kg per cycle), etoposide (4 mg/kg/d × 2 days per cycle), cyclophosphamide (65 mg/kg/d × 2 days per cycle) with mesna, and methotrexate (400 mg/kg per cycle) with leucovorin rescue. Following induction chemotherapy, eligible patients underwent a single myeloablative chemotherapy cycle with autologous stem-cell rescue. Results: Significant toxicities of this intensified regimen, including gastrointestinal and infectious toxicities, are described. Among the 21 patients enrolled, there were 17 complete responses (81%), two partial responses, one stable disease, and one progressive disease. The 3-year event-free survival and overall survival are 49% (95% CI, 27% to 72%) and 60% (95% CI, 36% to 84%), respectively. Conclusion: This intensified induction chemotherapy regimen is feasible and tolerable. With the majority of patients with disseminated medulloblastoma having M2 or M3 disease at diagnosis, the encouraging high response rate of this intensified induction regimen suggests that such an addition of methotrexate should be explored in future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2452 · Cited by 294
Cited by
Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis
Rutkowski, S., von Hoff, K., Emser, A., Zwiener, I., Pietsch, T., Figarella-Branger, D., Giangaspero, F., Ellison, D. W., Garre, M.-L., Biassoni, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2299 · Cited by 323
Self-citationMedulloblastoma in childhood: new biological advances
Crawford, J. R., MacDonald, T. J., & Packer, R. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70289-2 · Cited by 286
Grill, J., Sainte-Rose, C., Jouvet, A., Gentet, J.-C., Lejars, O., Frappaz, D., Doz, F., Rialland, X., Pichon, F., Bertozzi, A.-I., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70252-7 · Cited by 280
Metadata
- Authors
- Chi, S. N., Gardner, S. L., Levy, A. S., Knopp, E. A., Miller, D. C., Wisoff, J. H., Weiner, H. L., & Finlay, J. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-12-15
- Volume
- 22
- Issue
- 24
- Pages
- 4881-4887
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2036219526
- Cited by
- 177
- References
- 1
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma. https://app.cochat.ai/papers/10.1200/jco.2004.12.126
- The paper
- Chi, S. N., Gardner, S. L., Levy, A. S., Knopp, E. A., Miller, D. C., Wisoff, J. H., Weiner, H. L., & Finlay, J. L. (2004). Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.12.126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.